Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Concise Review
  • Published:

ABC transporters and drug resistance in leukemia: was P-gp nothing but the first head of the Hydra?

Abstract

More than 30 years ago it was discovered that permeability glycoprotein (P-gp) can cause drug resistance. Over the following decades numerous studies showed that high expression of P-gp is associated with poor prognosis in acute myeloid leukemia in adults and that it causes multidrug resistance via ATP-dependent drug efflux. It was hoped that an inhibition of P-gp could sensitize resistant leukemic cells to chemotherapy and thus improve treatment results. Today we know that the family of ATP-binding cassette transporters (ABC transporters) comprises 48 different proteins. Some of them seem to be able to cause drug resistance as well as P-gp. This review focuses on emerging data on the clinical relevance of other ABC transporters, such as BCRP, MRP3, and ABCA3. When Heracles fought the ancient Hydra, he had to fight all the heads at ones but only one head was vital for the beast. Can we block all the relevant ABC transporters at once? Is there one transporter that is more important than the others?

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Juliano RL, Ling V . A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 1976; 455: 152–162.

    Article  CAS  PubMed  Google Scholar 

  2. Kartner N, Riordan JR, Ling V . Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines. Science 1983; 221: 1285–1288.

    Article  CAS  PubMed  Google Scholar 

  3. Chen CJ, Chin JE, Ueda K, Clark DP, Pastan I, Gottesman MM et al. Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell 1986; 47: 381–389.

    Article  CAS  PubMed  Google Scholar 

  4. Marie JP, Zittoun R, Sikic BI . Multidrug resistance (mdr1) gene expression in adult acute leukemias: correlations with treatment outcome and in vitro drug sensitivity. Blood 1991; 78: 586–592.

    CAS  PubMed  Google Scholar 

  5. Szakacs G, Annereau JP, Lababidi S, Shankavaram U, Arciello A, Bussey KJ et al. Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells. Cancer Cell 2004; 6: 129–137.

    Article  CAS  PubMed  Google Scholar 

  6. Gillet JP, Efferth T, Steinbach D, Hamels J, de Longueville F, Bertholet V et al. Microarray-based detection of multidrug resistance in human tumor cells by expression profiling of ATP-binding cassette transporter genes. Cancer Res 2004; 64: 8987–8993.

    Article  CAS  PubMed  Google Scholar 

  7. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM . Targeting multidrug resistance in cancer. Nat Rev Drug Discov 2006; 5: 219–234.

    Article  CAS  PubMed  Google Scholar 

  8. Legrand O, Simonin G, Perrot JY, Zittoun R, Marie JP . Pgp and MRP activities using calcein-AM are prognostic factors in adult acute myeloid leukemia patients. Blood 1998; 91: 4480–4488.

    CAS  PubMed  Google Scholar 

  9. Leith CP, Kopecky KJ, Chen IM, Eijdems L, Slovak ML, McConnell TS et al. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study. Blood 1999; 94: 1086–1099.

    CAS  PubMed  Google Scholar 

  10. Leith CP, Kopecky KJ, Godwin J, McConnell T, Slovak ML, Chen IM et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood 1997; 89: 3323–3329.

    CAS  PubMed  Google Scholar 

  11. Wuchter C, Leonid K, Ruppert V, Schrappe M, Buchner T, Schoch C et al. Clinical significance of P-glycoprotein expression and function for response to induction chemotherapy, relapse rate and overall survival in acute leukemia. Haematologica 2000; 85: 711–721.

    CAS  PubMed  Google Scholar 

  12. Benderra Z, Faussat AM, Sayada L, Perrot JY, Chaoui D, Marie JP et al. Breast cancer resistance protein and P-glycoprotein in 149 adult acute myeloid leukemias. Clin Cancer Res 2004; 10: 7896–7902.

    Article  CAS  PubMed  Google Scholar 

  13. Schaich M, Soucek S, Thiede C, Ehninger G, Illmer T . MDR1 and MRP1 gene expression are independent predictors for treatment outcome in adult acute myeloid leukaemia. Br J Haematol 2005; 128: 324–332.

    Article  CAS  PubMed  Google Scholar 

  14. Sievers EL, Smith FO, Woods WG, Lee JW, Bleyer WA, Willman CL et al. Cell surface expression of the multidrug resistance P-glycoprotein (P-170) as detected by monoclonal antibody MRK-16 in pediatric acute myeloid leukemia fails to define a poor prognostic group: a report from the Childrens Cancer Group. Leukemia 1995; 9: 2042–2048.

    CAS  PubMed  Google Scholar 

  15. Steinbach D, Furchtbar S, Sell W, Lengemann J, Hermann J, Zintl F et al. Contrary to adult patients, expression of the multidrug resistance gene (MDR1) fails to define a poor prognostic group in childhood AML. Leukemia 2003; 17: 470–471.

    Article  CAS  PubMed  Google Scholar 

  16. Suarez L, Vidriales MB, Moreno MJ, Lopez A, Garcia-Larana J, Perez-Lopez C et al. Differences in anti-apoptotic and multidrug resistance phenotypes in elderly and young acute myeloid leukemia patients are related to the maturation of blast cells. Haematologica 2005; 90: 54–59.

    CAS  PubMed  Google Scholar 

  17. Kanerva J, Tiirikainen MI, Makipernaa A, Riikonen P, Mottonen M, Salmi TT et al. Initial P-glycoprotein expression in childhood acute lymphoblastic leukemia: no evidence of prognostic impact in follow-up. Pediatr Hematol Oncol 2001; 18: 27–36.

    Article  CAS  PubMed  Google Scholar 

  18. den Boer ML, Pieters R, Kazemier KM, Rottier MM, Zwaan CM, Kaspers GJ et al. Relationship between major vault protein/lung resistance protein, multidrug resistance-associated protein, P-glycoprotein expression, and drug resistance in childhood leukemia. Blood 1998; 91: 2092–2098.

    CAS  PubMed  Google Scholar 

  19. Olson DP, Taylor BJ, La M, Sather H, Reaman GH, Ivy SP . The prognostic significance of P-glycoprotein, multidrug resistance-related protein 1 and lung resistance protein in pediatric acute lymphoblastic leukemia: a retrospective study of 295 newly diagnosed patients by the Children's Oncology Group. Leuk Lymphoma 2005; 46: 681–691.

    Article  CAS  PubMed  Google Scholar 

  20. Casale F, D'Angelo V, Addeo R, Caraglia M, Crisci S, Rondelli R et al. P-glycoprotein 170 expression and function as an adverse independent prognostic factor in childhood acute lymphoblastic leukemia. Oncol Rep 2004; 12: 1201–1207.

    CAS  PubMed  Google Scholar 

  21. De Moerloose B, Swerts K, Benoit Y, Laureys G, Loeys T, Philippe J et al. The combined analysis of P-glycoprotein expression and activity predicts outcome in childhood acute lymphoblastic leukemia. Pediatr Hematol Oncol 2003; 20: 381–391.

    Article  CAS  PubMed  Google Scholar 

  22. Plasschaert SL, Vellenga E, de Bont ES, van der Kolk DM, Veerman AJ, Sluiter WJ et al. High functional P-glycoprotein activity is more often present in T-cell acute lymphoblastic leukaemic cells in adults than in children. Leuk Lymphoma 2003; 44: 85–95.

    Article  CAS  PubMed  Google Scholar 

  23. Vitale A, Guarini A, Ariola C, Mancini M, Mecucci C, Cuneo A et al. Adult T-cell acute lymphoblastic leukemia: biologic profile at presentation and correlation with response to induction treatment in patients enrolled in the GIMEMA LAL 0496 protocol. Blood 2006; 107: 473–479.

    Article  CAS  PubMed  Google Scholar 

  24. Tafuri A, Gregorj C, Petrucci MT, Ricciardi MR, Mancini M, Cimino G et al. MDR1 protein expression is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia. Blood 2002; 100: 974–981.

    Article  CAS  PubMed  Google Scholar 

  25. Damiani D, Michelutti A, Michieli M, Masolini P, Stocchi R, Geromin A et al. P-glycoprotein, lung resistance-related protein and multidrug resistance-associated protein in de novo adult acute lymphoblastic leukaemia. Br J Haematol 2002; 116: 519–527.

    Article  CAS  PubMed  Google Scholar 

  26. Goasguen JE, Dossot JM, Fardel O, Le Mee F, Le Gall E, Leblay R et al. Expression of the multidrug resistance-associated P-glycoprotein (P-170) in 59 cases of de novo acute lymphoblastic leukemia: prognostic implications. Blood 1993; 81: 2394–2398.

    CAS  PubMed  Google Scholar 

  27. Ross DD, Yang W, Abruzzo LV, Dalton WS, Schneider E, Lage H et al. Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines. J Natl Cancer Inst 1999; 91: 429–433.

    Article  CAS  PubMed  Google Scholar 

  28. Allikmets R, Schriml LM, Hutchinson A, Romano-Spica V, Dean M . A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. Cancer Res 1998; 58: 5337–5339.

    CAS  PubMed  Google Scholar 

  29. Miyake K, Mickley L, Litman T, Zhan Z, Robey R, Cristensen B et al. Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes. Cancer Res 1999; 59: 8–13.

    CAS  PubMed  Google Scholar 

  30. Maliepaard M, Scheffer GL, Faneyte IF, van Gastelen MA, Pijnenborg AC, Schinkel AH et al. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res 2001; 61: 3458–3464.

    CAS  PubMed  Google Scholar 

  31. Steinbach D, Sell W, Voigt A, Hermann J, Zintl F, Sauerbrey A . BCRP gene expression is associated with a poor response to remission induction therapy in childhood acute myeloid leukemia. Leukemia 2002; 16: 1443–1447.

    Article  CAS  PubMed  Google Scholar 

  32. Uggla B, Stahl E, Wagsater D, Paul C, Karlsson MG, Sirsjo A et al. BCRP mRNA expression v. clinical outcome in 40 adult AML patients. Leuk Res 2005; 29: 141–146.

    Article  CAS  PubMed  Google Scholar 

  33. Damiani D, Tiribelli M, Calistri E, Geromin A, Chiarvesio A, Michelutti A et al. The prognostic value of P-glycoprotein (ABCB) and breast cancer resistance protein (ABCG2) in adults with de novo acute myeloid leukemia with normal karyotype. Haematologica 2006; 91: 825–828.

    CAS  PubMed  Google Scholar 

  34. Benderra Z, Faussat AM, Sayada L, Perrot JY, Tang R, Chaoui D et al. MRP3, BCRP, and P-glycoprotein activities are prognostic factors in adult acute myeloid leukemia. Clin Cancer Res 2005; 11: 7764–7772.

    Article  CAS  PubMed  Google Scholar 

  35. Plasschaert SL, van der Kolk DM, de Bont ES, Kamps WA, Morisaki K, Bates SE et al. The role of breast cancer resistance protein in acute lymphoblastic leukemia. Clin Cancer Res 2003; 9: 5171–5177.

    CAS  PubMed  Google Scholar 

  36. Sauerbrey A, Sell W, Steinbach D, Voigt A, Zintl F . Expression of the BCRP gene (ABCG2/MXR/ABCP) in childhood acute lymphoblastic leukaemia. Br J Haematol 2002; 118: 147–150.

    Article  CAS  PubMed  Google Scholar 

  37. Stam RW, van den Heuvel-Eibrink MM, den Boer ML, Ebus ME, Janka-Schaub GE, Allen JD et al. Multidrug resistance genes in infant acute lymphoblastic leukemia: Ara-C is not a substrate for the breast cancer resistance protein. Leukemia 2004; 18: 78–83.

    Article  CAS  PubMed  Google Scholar 

  38. Suvannasankha A, Minderman H, O'Loughlin KL, Nakanishi T, Ford LA, Greco WR et al. Breast cancer resistance protein (BCRP/MXR/ABCG2) in adult acute lymphoblastic leukaemia: frequent expression and possible correlation with shorter disease-free survival. Br J Haematol 2004; 127: 392–398.

    Article  CAS  PubMed  Google Scholar 

  39. Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992; 258: 1650–1654.

    Article  CAS  PubMed  Google Scholar 

  40. Laupeze B, Amiot L, Drenou B, Bernard M, Branger B, Grosset JM et al. High multidrug resistance protein activity in acute myeloid leukaemias is associated with poor response to chemotherapy and reduced patient survival. Br J Haematol 2002; 116: 834–838.

    Article  CAS  PubMed  Google Scholar 

  41. Legrand O, Simonin G, Perrot JY, Zittoun R, Marie JP . Both Pgp and MRP1 activities using calcein-AM contribute to drug resistance in AML. Adv Exp Med Biol 1999; 457: 161–175.

    Article  CAS  PubMed  Google Scholar 

  42. Borg AG, Burgess R, Green LM, Scheper RJ, Yin JA . Overexpression of lung-resistance protein and increased P-glycoprotein function in acute myeloid leukaemia cells predict a poor response to chemotherapy and reduced patient survival. Br J Haematol 1998; 103: 1083–1091.

    Article  CAS  PubMed  Google Scholar 

  43. van der Kolk DM, de Vries EG, van Putten WJ, Verdonck LF, Ossenkoppele GJ, Verhoef GE et al. P-glycoprotein and multidrug resistance protein activities in relation to treatment outcome in acute myeloid leukemia. Clin Cancer Res 2000; 6: 3205–3214.

    CAS  PubMed  Google Scholar 

  44. Filipits M, Suchomel RW, Zochbauer S, Brunner R, Lechner K, Pirker R . Multidrug resistance-associated protein in acute myeloid leukemia: no impact on treatment outcome. Clin Cancer Res 1997; 3: 1419–1425.

    CAS  PubMed  Google Scholar 

  45. Taksin AL, Legrand O, Raffoux E, de Revel T, Thomas X, Contentin N et al. High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group. Leukemia 2007; 21: 66–71.

    Article  CAS  PubMed  Google Scholar 

  46. Walter RB, Raden BW, Hong TC, Flowers DA, Bernstein ID, Linenberger ML . Multidrug resistance protein attenuates gemtuzumab ozogamicin-induced cytotoxicity in acute myeloid leukemia cells. Blood 2003; 102: 1466–1473.

    Article  CAS  PubMed  Google Scholar 

  47. Steinbach D, Lengemann J, Voigt A, Hermann J, Zintl F, Sauerbrey A . Response to chemotherapy and expression of the genes encoding the multidrug resistance-associated proteins MRP2, MRP3, MRP4, MRP5, and SMRP in childhood acute myeloid leukemia. Clin Cancer Res 2003; 9: 1083–1086.

    CAS  PubMed  Google Scholar 

  48. Steinbach D, Wittig S, Cario G, Viehmann S, Mueller A, Gruhn B et al. The multidrug resistance-associated protein 3 (MRP3) is associated with a poor outcome in childhood ALL and may account for the worse prognosis in male patients and T-cell immunophenotype. Blood 2003; 102: 4493–4498.

    Article  CAS  PubMed  Google Scholar 

  49. Plasschaert SL, de Bont ES, Boezen M, van der Kolk DM, Daenen SM, Faber KN et al. Expression of multidrug resistance-associated proteins predicts prognosis in childhood and adult acute lymphoblastic leukemia. Clin Cancer Res 2005; 11: 8661–8668.

    Article  CAS  PubMed  Google Scholar 

  50. Kool M, van der Linden M, de Haas M, Scheffer GL, de Vree JM, Smith AJ et al. MRP3, an organic anion transporter able to transport anti-cancer drugs. Proc Natl Acad Sci USA 1999; 96: 6914–6919.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Zelcer N, Saeki T, Reid G, Beijnen JH, Borst P . Characterization of drug transport by the human multidrug resistance protein 3 (ABCC3). J Biol Chem 2001; 276: 46400–46407.

    Article  CAS  PubMed  Google Scholar 

  52. Yasui K, Mihara S, Zhao C, Okamoto H, Saito-Ohara F, Tomida A et al. Alteration in copy numbers of genes as a mechanism for acquired drug resistance. Cancer Res 2004; 64: 1403–1410.

    Article  CAS  PubMed  Google Scholar 

  53. Hirschmann-Jax C, Foster AE, Wulf GG, Nuchtern JG, Jax TW, Gobel U et al. A distinct ‘side population’ of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci USA 2004; 101: 14228–14233.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Norwood K, Wang RY, Hirschmann-Jax C, Andreeff M, Brenner MK, Goodell MA et al. An in vivo propagated human acute myeloid leukemia expressing ABCA3. Leuk Res 2004; 28: 295–299.

    Article  CAS  PubMed  Google Scholar 

  55. Wulf GG, Modlich S, Inagaki N, Reinhardt D, Schroers R, Griesinger F et al. ABC transporter ABCA3 is expressed in acute myeloid leukemia blast cells and participates in vesicular transport. Haematologica 2004; 89: 1395–1397.

    CAS  PubMed  Google Scholar 

  56. Steinbach D, Gillet JP, Sauerbrey A, Gruhn B, Dawczynski K, Bertholet V et al. ABCA3 as a possible cause of drug resistance in childhood acute myeloid leukemia. Clin Cancer Res 2006; 12: 4357–4363.

    Article  CAS  PubMed  Google Scholar 

  57. Yamano G, Funahashi H, Kawanami O, Zhao LX, Ban N, Uchida Y et al. ABCA3 is a lamellar body membrane protein in human lung alveolar type II cells. FEBS Lett 2001; 508: 221–225.

    Article  CAS  PubMed  Google Scholar 

  58. Efferth T, Gillet JP, Sauerbrey A, Zintl F, Bertholet V, de Longueville F et al. Expression profiling of ATP-binding cassette transporters in childhood T-cell acute lymphoblastic leukemia. Mol Cancer Ther 2006; 5: 1986–1994.

    Article  CAS  PubMed  Google Scholar 

  59. Becton D, Dahl GV, Ravindranath Y, Chang MN, Behm FG, Raimondi SC et al. Randomized use of cyclosporin A (CsA) to modulate P-glycoprotein in children with AML in remission: Pediatric Oncology Group Study 9421. Blood 2006; 107: 1315–1324.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. van der Holt B, Lowenberg B, Burnett AK, Knauf WU, Shepherd J, Piccaluga PP et al. The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis. Blood 2005; 106: 2646–2654.

    Article  CAS  PubMed  Google Scholar 

  61. Solary E, Drenou B, Campos L, de Cremoux P, Mugneret F, Moreau P et al. Quinine as a multidrug resistance inhibitor: a phase 3 multicentric randomized study in adult de novo acute myelogenous leukemia. Blood 2003; 102: 1202–1210.

    Article  CAS  PubMed  Google Scholar 

  62. List AF, Kopecky KJ, Willman CL, Head DR, Persons DL, Slovak ML et al. Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. Blood 2001; 98: 3212–3220.

    Article  CAS  PubMed  Google Scholar 

  63. Wattel E, Solary E, Hecquet B, Caillot D, Ifrah N, Brion A et al. Quinine improves the results of intensive chemotherapy in myelodysplastic syndromes expressing P glycoprotein: results of a randomized study. Br J Haematol 1998; 102: 1015–1024.

    Article  CAS  PubMed  Google Scholar 

  64. Qadir M, O'Loughlin KL, Fricke SM, Williamson NA, Greco WR, Minderman H et al. Cyclosporin A is a broad-spectrum multidrug resistance modulator. Clin Cancer Res 2005; 11: 2320–2326.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to D Steinbach.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Steinbach, D., Legrand, O. ABC transporters and drug resistance in leukemia: was P-gp nothing but the first head of the Hydra?. Leukemia 21, 1172–1176 (2007). https://doi.org/10.1038/sj.leu.2404692

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2404692

Keywords

This article is cited by

Search

Quick links